NCT00770848 - AMG 102 in Combination With Mitoxantrone and Prednisone in Subjects With Previously Treated Castrate Resistant Prostate Cancer | Biotech Hunter

Enrollment

162

Participants

Timeline

Start Date

November 30, 2008

Primary Completion Date

January 31, 2011

Study Completion Date

April 30, 2012

Conditions

CancerCastrate-Resistant Prostate CancerMestastatic Prostate CancerProstate Cancer

Interventions

DRUG

AMG 102

Investigational product to be given at safe dose from phase 1b, will be administered by IV Q3W.

DRUG

AMG 102

Investigational product to be given at 15mg/kg, 7.5mg/kg, or 5mg/kg depending on assignment, will be administered by IV Q3W.

DRUG

Mitoxantrone

Administered Q3W for a maximum of 12 cyles

DRUG

Placebo

DRUG

Prednisone

5 mg orally BID